Conclusions: The present study indicated that high expression of WDR72 may indicate a good prognosis of patients treated with Nivolumab and WDR72 expression combined with PBRM1 mutation could be more persuasive to predict the response for ICT in ccRCC patients. The gene discussed is WDR72; the disease is nonpapillary renal cell carcinoma.